Gilead Sciences's Total Assets for the quarter that ended in Dec. 2023 was $62,125 Mil.
Warning Sign:
If a company builds assets at 11.2% a year, faster than its revenue growth rate of 5.7% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Gilead Sciences's average Total Assets Growth Rate was -3.40% per year.
During the past 3 years, the average Total Assets Growth Rate was -3.50% per year.
During the past 5 years, the average Total Assets Growth Rate was 11.20% per year.
During the past 10 years, the average Total Assets Growth Rate was 9.70% per year.
During the past 13 years, Gilead Sciences's highest 3-Year average Total Assets Growth Rate was 272.40%. The lowest was -19.80%. And the median was 29.65%.
Total Assets is connected with ROA %. Gilead Sciences's annualizedROA % for the quarter that ended in Dec. 2023 was 9.18%. Total Assets is also linked to Revenue through Asset Turnover. Gilead Sciences's Asset Turnover for the quarter that ended in Dec. 2023 was 0.11.
Gilead Sciences Total Assets Historical Data
The historical data trend for Gilead Sciences's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Gilead Sciences's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gilead Sciences (NAS:GILD) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Gilead Sciences's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Gilead Sciences Total Assets Related Terms
Thank you for viewing the detailed overview of Gilead Sciences's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Gilead Sciences (Gilead Sciences) Business Description
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GILD has been successfully added to your 